Bone marrow transplantation (BMT) benefits nonmalignant diseases but is limited by regimen-related toxicity, graft-versus-host disease (GVHD), donor availability, and graft rejection (GR). To overcome some of these barriers, we developed a new conditioning strategy for these patients. In total, 16 patients received Campath-1H (33/ 48 mg; days À21 to À19), fludarabine (150 mg/m 2 ; days À8 to À4), melphalan (140/70 mg/m 2 ; day À3), and transplant using related/unrelated stem cells. GVHD prophylaxis included cyclosporine/methylprednisolone for cord cells. Other recipients also received methotrexate. Risk factors for GR included multiple transfusions (6), low stem cell numbers (1), and immunologic/ metabolic disorders (3).
regimen; nonmalignant; metabolic disorders; stem cell Stem cell transplantation (SCT) is the treatment of choice for several nonmalignant disorders where establishment of normal donor hematopoiesis reverses or halts disease progression. 1, 2 However, this treatment option is often not considered, or delayed, due to potential treatment related morbidity and mortality. Limitations to SCT in nonmalignant disorders include increased rates of graft rejection (GR) due to host immune competence, lack of suitably matched donors, infections, graft-versus-host disease (GVHD), and early/late irreversible sequelae of conditioning. 3, 4 Strategies to overcome these barriers require successful engraftment of stem cells irrespective of the source with minimal short-and long-term transplant-related complications. 5 Recent studies using nonmyeloablative or reducedintensity transplants seek to limit side effects by using less intense, better tolerated regimen. Unfortunately, especially in the case of nonmalignant disorders, this often results in higher rates of GR. 6 Studies targeted at developing 'ideal' and 'safe' regimen that can surmount these barriers is a common goal for transplant centers.
In an effort to achieve successful, stable engraftment with any suitable donor stem cell source and minimize toxicity in nonmalignant disorder transplants, we developed a new reduced-intensity conditioning regimen aimed at significantly suppressing the recipient's immune system to facilitate engraftment. Study objectives were to follow engraftment, transplant-related toxicities and GVHD. The study was also designed to determine the level of host immune suppression necessary to achieve successful engraftment when stratified by stem cell source; bone marrow (BM), peripheral blood (PB) and umbilical cord blood (UCB). This report describes transplant outcomes in the first 16 patients treated with this approach. Both adult and pediatric recipients underwent successful transplantation even when considered at high risk of GR. In addition, none experienced significant GVHD.
Study design
Between December 2001 and June 2004, 16 recipients with nonmalignant disorders received SCT using the best available stem cell source based on HLA-A, B, and DR high-resolution typing. In matched related donors, the choice of the stem cell source from the donor was based on the donor and/or family's preference. BM was requested as the preferred stem cell source if the donor was unrelated. The stem cell product was considered acceptable if the total nucleated cell count (TNC) was X2.5 Â 10 8 or CD34 cell count X2.5 Â 10 6 /kg for BM and PB; TNCX2.0 Â 10 7 or CD34 X2.0 Â 10 5 /kg for UCB. Approval for transplant was obtained from Institutional Review Boards of participating institutions, and written informed consent was obtained from all patients. The conditioning regimen consisted of intravenous (i.v.) Campath-1H (Alemtuzumab) on days À21 (10 mg), À20 (15 mg), and À19 (20 mg) following a test dose (3 mg). The dose was reduced to 10 mg each day ( Â 3) following the test dose of 3 mg (3-10-10-10 mg) in children o10 kg. In contrast to previous studies, and based on pharmacokinetic data, Campath-1H was timed to provide more host immune suppression and less in vivo donor T-cell depletion. 7, 8 I.v. fludarabine (30 mg/m 2 / day) was administered on days À8 to À4; i.v. melphalan: 140 mg/m 2 -first dose level (n ¼ 15), 70 mg/m 2 -second dose level (n ¼ 1) was administered on day À3. Stem cells were infused on day 0 after 2 rest days. Based on a phase II design, the melphalan dose was de-escalated to 70 mg/m 2 when target accrual to individual cohorts based on stem cell source (BM, PB, and UCB) was successfully completed. For GVHD prophylaxis, CSA (trough maintained 250-350 ng/ml) (determined by fluorescence polarization immunoassay -Abbott Laboratories, IL, USA) was commenced on day À2 and tapered after day þ 100. Methylprednisolone (MP) (1 mg/kg/day) was commenced on day þ 7 and tapered after day þ 28. Methotrexate (10 mg/m 2 on day þ 1, 7.5 mg/m 2 on days þ 3 and þ 6) was administered only to recipients of BM and PB. Acute and chronic GVHD were graded according to established criteria. 9, 10 All recipients received G-CSF (5 mcg/kg/day) i.v. from day þ 7 until ANC X1.5 Â 10 9 /l Â 3. Engraftment was evaluated by short tandem repeat (STR) DNA analysis of PB (fractionated into myeloid/ lymphoid populations) and/or BM at 1, 3, 6, 9, 12, 18, and 24 months post transplant. Immune reconstitution was monitored at the same time points by flow cytometry analysis to determine absolute lymphocyte count (ALC), CD3, CD4, CD8, CD19, and CD16 þ 56 cell numbers, T-cell proliferation assays against phytohemagglutinin (PHA), B cell proliferation against pokweed mitogen (PWM), quantitation of immunoglobulin levels (IgG, A, and M), and tetanus toxoid antibody titers.
Infection prophylaxis was provided by sulfamethoxazole þ trimethoprim (1 year), acyclovir (if HSV þ ) (180 days) and itraconazole (100 days). Later patients (4) also received bacterial prophylaxis with ciprofloxacin (day 100). Weekly monitoring for CMV was performed by quantitative CMV PCR (100 days). Patients were treated preemptively for positive or rising CMV levels.
Results
Recipient characteristics and diagnoses are listed in Table 1 . The regimen was well tolerated. Side effects included transient fever and urticaria during Campath-1H infusion (n ¼ 5), mild self-limiting nausea and/or anorexia following melphalan (n ¼ 4), and postconditioning urethral discomfort (n ¼ 6) that resolved by day þ 12. The etiology of urethral discomfort was unclear and presumed to be due to urethral mucositis as no infectious etiology was documented. Patient #14 ( /kg) in the UCB product requested and accepted, but had low numbers of cells infused post thaw (Table 1) .
Hematopoietic recovery, the most recent chimerism data, and GVHD incidence and grading are shown in Table 1 with reference to the stem cell source and diagnosis. The median duration of follow-up was 281 days (78-907), and overall survival was 75%. Neutropenia (ANCp0.5 Â 10 /l) only on day 103 after partial splenectomy. Unlike other reduced-intensity regimens, 11, 12 full donor engraftment was achieved in BM by day þ 30 each time. There were no late GR or changes in chimerism levels after engraftment. Two patients have continued stable mixed peripheral blood lymphoid chimerism (Table 1) . Disease parameters stabilized, improved or resolved in all survivors. Successful engraftment was achieved in recipients considered at increased risk for GR; Hurler syndrome (n ¼ 2), chronic transfusion therapy for 46 months (n ¼ 6), low UCB cell dose (n ¼ 1), and X-linked autoimmunity-allergic disregulation syndrome (XLAAD) (n ¼ 1). 13 Acute GVHD was seen in only four patients (28%) and restricted to grade I or II skin involvement. Nine patients have discontinued GVHD prophylaxis as scheduled; the others are tapering immune suppression successfully as planned. No recipient that survived 4100 days developed chronic GVHD. One patient became pregnant on day þ 240 post transplant, and went on to deliver healthy twins following an uncomplicated pregnancy.
Toxicities during the first year post transplant are shown in Table 2 . Infectious complications (bacterial and viral) were the most frequent transplant-related complications and occurred predominantly in the early post transplant period (o100 days). Six of seven CMV positive recipients and one CMV negative recipient reactivated CMV that was detected by quantitative PCR testing. The CMV negative recipient received stem cells from a CMV positive donor. All but one recipient responded to preemptive therapy for CMV. The only exception died of CMV disease of the gut/ lung and TTP despite treatment with gancyclovir and foscarnet. A mutation in gene UL 97 (M460V) specific for gancyclovir resistance was detected post mortem.
14 One CMV positive recipient who was transplanted from a CMV þ donor did not develop CMV replication. CMV Campath-1H for nonmalignant disease transplants S Shenoy et al Campath-1H for nonmalignant disease transplants S Shenoy et al reactivation was consistently detected early post transplant between 20 and 60 days. There were two deaths from Pseudomonas sepsis prior to engraftment on days þ 6 and þ 14. Both patients (diagnoses: HLH and SAA) had documented Pseudomonas infections (lung and central line respectively) just prior to transplant. Pseudomonas sp. cultured from the lung and blood at autopsy was resistant to all antibiotics in the former of these patients. Other infections encountered in recurrent manner included HHV 6, BK virus, Staphylococcus sp., and Clostridium difficile ( Table 2 ). These infections were tested for based on symptoms such as fever and/or skin rash, decreased blood counts (HHV6), microscopic hematuria (BK virus), diarrhea (C. difficile), etc. Specific therapy, if available, was instituted at the time an infection was identified. One patient (adult; UCBT) died of sudden intracranial hemorrhage on day 49, after donor engraftment but before platelet recovery, following prolonged and severe refractory untreated thrombocytopenia (platelets persistently o10 Â 10 9 /l). Other organ toxicities (seizures, confusion, dizziness, 3 hepatotoxicity, 1 nephrotoxicity 1 ) were reversible and likely secondary to immune suppression (CSA) or supportive care (voriconazole).
Immune reconstitution was determined at 1, 3, 6, 9, 12, 18 and 24 months. Median ALC and absolute numbers of CD3 (Figure 1a) , CD4, and CD8 (Figure 1b) , B (CD19), and NK (CD16 þ 56) (Figure 1c) are shown, demonstrating gradual recovery after the first 3 months. CD4 þ T cells and B cells, which were markedly depleted early, had recovered to approximately 50% normal by 3 months, and normalized between 6 and 9 months. This recovery contrasted with delayed (418 months) lymphocyte recovery in patients receiving Campath-1H in the immediate pretransplant period. 12 Lymphocyte proliferation with PWM and PHA are shown in Figure 2a as percentages of normal controls that were run simultaneously. Recovery of lymphocyte stimulation to mitogen paralleled recovery of lymphocyte numbers. Immunoglobulin A and M levels are shown in Figure 2b . Both were initially low, recovering after 6 months. IgG levels, in contrast, remained within the normal range of 345-1213 mg/dl (not shown). Median IgG levels at 1, 3, 6, 9, 12, 18, and 24 months were 538, 963, 780, 1110, 916.5, 956, and 823 mg/dl, respectively. One UCB recipient received IVIG prophylaxis every 3 weeks for 100 days post transplant and another received CMV hyperimmuneglobulin for CMV reactivation at day þ 50. Immunoglobulin levels and tetanus toxoid antibody titers were not monitored in these two patients for 3 months following immunoglobulin prophylaxis and are not included in the analysis. Tetanus toxoid antibody titers were determined at the same time points in the first year. Median titers were 0.3, 0.2, 0.125, 0.05, and 0.2 respectively (normal X0.1 IU/ml). The decrease in titer (lowest at 9 months) occurred following a lag time of a few months after the initial decrease in circulating CD19 þ B cell numbers that were lowest at 1 and 3 months post transplant. There was a trend toward recovery and normalization at 12 months, prior to resumption of immunization. Thus, tetanus specific titers did not correlate with IgG levels. Predictably, immune reconstitution paralleled withdrawal of immunosuppression and GVHD prophylaxis.
Discussion
We describe a reduced-intensity transplant regimen that supported successful engraftment of BM, PB, and UCB, in both adult and pediatric stem cell transplant recipients with nonmalignant disorders. At median follow-up of 281 days (range 78-907), all survivors (75%) were doing well with reversal or improvement of their underlying disease. Trilineage donor hematopoietic engraftment was present within 1 month of transplant. This was in contrast to delayed engraftment patterns with other reduced-intensity regimen where donor engraftment is seen in gradual manner, sometimes as late as 18 months following transplant. 11, 12 Engraftment remained stable after tapering immunosuppression; no late GRs were encountered. 15, 16 These results are encouraging given the reported high The conditioning regimen was well tolerated except for mild infusion reactions such as fever and urticaria with Campath-1H infusion and transient urethral discomfort during the neutropenic period. All recipients successfully completed conditioning as planned. Of note, one transplant recipient had high hepatic iron deposition (serum ferritin 1520 ng/ml; hepatic iron 25 mg/g dry liver weight) and early hepatic fibrosis by trichrome stain, induced by chronic red cell transfusion therapy for Hb E/b Thalassemia. 17 Conditioning was uneventful in this recipient. We did not see increased organ toxicities or GVHD previously described with conditioning regimen using fludarabine and melphalan. 19, 20 Myeloablative conditioning strategies are associated with early and late regimen related organ toxicities especially in the pediatric age group, some of which are irreversible. 2, 3, 5 Of particular concern in pediatrics are growth, development, fertility, endocrine function, and long-term organ toxicities, all of which are influenced by the dose and combination of conditioning chemotherapy and radiation. [21] [22] [23] [24] [25] A important reason for developing new transplant strategies with reduced-intensity conditioning is to offset some of the early and late toxicities associated with the conditioning regimen. 26 Though targeted to reduce regimen-related toxicity, a reduced intensity or nonmyeloablative approach could tip the balance in favor of GR, especially in the immune competent host. 6 The risk of GR is also higher with unrelated donor cells, cord transplants with low stem cell numbers, and in recipients of multiple blood products presumably due to alloimmunization. 6, 27, 28 The ideal regimen would be one that affords long-term stable engraftment with low toxicity, using the best available stem cell source, since the stem cell source is often the limiting factor to timely transplantation. With this regimen, we encountered no limiting early organ toxicities during conditioning. Toxicities were predominantly post transplant infections that required close monitoring and timely appropriate intervention for a finite period of time until immune reconstitution. In an effort to further decrease late toxicity, a dose de-escalation design is adopted; the first patient transplanted with a melphalan dose of 70 mg/m 2 has engrafted and further evaluation of this dose is in progress. Pregnancy in one recipient that culminated in the delivery of normal twins is encouraging for the potential preservation of gonadal function in females. Male gonadal function will need to be assessed as the study proceeds. Human sperm has CD52 expression and is capable of binding the drug. 29 Germ cell and Leydig cell damage has been described in adult recipients of Campath-1H (with fludarabine and melphalan) in a similar manner to myeloablative therapies. 
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The incidence of acute GVHD was low (28%) and was restricted to the skin (grade 1-2) ( Table 1 ). When present, GVHD was easily controlled with topical steroids and an extended MP taper. Recipients 46 months post transplant were either off all immune suppression (n ¼ 9) or on a CSA taper (n ¼ 3). There was no GVHD recurrence after immune suppression was tapered or discontinued. No recipient developed chronic GVHD. The low incidence of GVHD is attributable to depletion of T and B cells by Campath-1H, a humanized monoclonal antibody that efficiently depletes CD52 þ cells. 31, 32 This is reflected in the significantly low CD4 þ T cell and CD19 þ B cell numbers in the first 3 months post transplant. Peripheral circulating monocytes and monocyte derived dendritic cells are also effectively depleted by Campath-1H. 32, 33 The reduced ability to present host antigens to donor T cells may be of added benefit in controlling GVHD. Interestingly, only myeloid derived dendritic cell subsets express CD52 and are targeted for depletion, whereas Langerhans cells and dermal-interstitial DCs are not. 34 It is speculated that this selective sparing and early recovery of donorderived DCs after transplant may help in immune reconstitution. Dendritic cell numbers and subsets were not monitored in this study. Peripheral blood monocyte numbers recovered in parallel with neutrophil counts (data not shown).
Immune reconstitution studies were helpful in determining patterns of lymphocyte depletion and recovery. Campath-1H for SCT conditioning has been previously reported to cause near total depletion of lymphocytes, especially CD4 þ and CD8 þ T cells, CD56 þ NK cells and CD19 þ B cells. 35 We observed near total depletion of CD4 þ T cells and B cells, with relative sparing of NK cells and CD8 þ T cells. In contrast to previous reports, lymphocyte recovery was evident after 3 months and normalized by 9 months post transplant. This may be due to our schedule and dosing of Campath-1H administration. T and B cell recovery takes up to 18 months when Campath-1H is given within the week prior to transplant. 12 The dose of Campath-1H used in our patients is also less than the 100 mg dose previously used. Further, the majority of patients had received no previous cytolytic chemotherapy and may have thus bound and consumed the Campath-1H in rapid manner. IgM and A levels were low during the first 3 months and recovered by 6 months, whereas IgG levels remained stable. Tetanus toxoid antibody titers declined only after the first 3 months, well after B cell depletion that occurred early. The kinetics of immune reconstitution was overall faster than in previously reported T depleted transplants, which are complicated by late immune constitution and high rates of GR. 36 Although pharmacokinetic studies for Campath-1H were not performed in this group of patients, CD4 þ T cell and CD19 þ B cell recovery began early, within the first 100 days post transplant, suggesting clearance of circulating drug within the first few months post transplant (Figure 1b  and c) . This is in contrast to previous reports of delayed immune reconstitution following peritransplant or ex vivo Campath-1H conditioning, where cellular immune reconstitution is delayed for over a year. [37] [38] [39] This delay in T and B cell immune reconstitution which translates into late onset infections resulting in morbidity and mortality, was not seen in our transplant recipients who had few infectious complications after the first 3 months. 37, 40, 41 The timing and dosing schedule we used for Campath-1H were different from previous studies. The maximum total dose of Campath-1H used was 48 mg even in adult recipients, in contrast to 100 mg previously used in vivo. 7 At the 100 mg dose peritransplant, Campath-1H was detected in circulation for up to 56 days. 8 We believe that the variation in dose and timing of Campath-1H allows for both sufficient host immune suppression and a shorter period of graft T cell depletion. This approach could provide the immune suppression necessary for engraftment, lower GVHD rates, and facilitate early immune reconstitution, all factors necessary for successful transplantation. Future patients transplanted on this study will have Campath-1H pharmacokinetics serially monitored by a sensitive newly developed ELISA assay at BioAnaLab Ltd, Oxford, UK. This should provide additional insight into the optimum dosing and timing of Campath-1H as transplant conditioning. Since there is no data on optimum dosing of Campath-1H in adults, and even less in children, the dose administered in this study while lower than that previously used, certainly has room for further adjustment and modification.
The predominant complications encountered were early onset infections, the majority of which were successfully treated or subsided with supportive care (Table 2) . Infections are a frequent complication of immunosuppression and T cell depleting regimens. [41] [42] [43] [44] Three of the four deaths in this study were due to infectious complications. Both bacterial infections that resulted in mortality were detected just prior to transplant, a complication previously described. 45 The third patient succumbed to CMV infection despite initial gancyclovir and later foscarnet therapy. The CMV isolated from this patient was found to carry a UL 937 mutation, accounting for resistance to treatment. The majority of CMV þ recipients (83%) reactivated CMV within a month of transplant. Based on our current experience, and the expanding knowledge of infection risks with Campath-1H, patients are now transplanted when free of invasive bacterial infections for 3 months, and receiving bacterial and fungal prophylaxis. Fatal infections have not been encountered since. Continued monitoring and timely intervention for infections (bacterial, fungal, and viral, and especially CMV) is important during the period of severe lymphopenia, and was largely limited to the first 100 days in this study. In contrast to previous reports of late CMV infection/disease with high mortality, with this conditioning approach, CMV is limited predominantly to the early post transplant period (o100 days) to date and further followup is in progress. 40, 44 In summary, this reduced-intensity approach to conditioning was developed using Campath-1H in a novel manner that provided significant host immune suppression to facilitate engraftment, while minimizing GVHD and GR. Continued monitoring for engraftment, delayed toxicities, and quality of life are ongoing. To date, we have not seen any variability in engraftment, GVHD, or GR based on indication for transplant or stem cell source. This approach appears promising for transplanting patients with nonmalignant disorders, provided adequate monitoring and infection prophylaxis are provided in timely manner. In addition, it provides a transplant approach for such patients with minimal conditioning related toxicities and engraftment irrespective of stem cell source. With a better understanding of Campath-1H pharmacokinetics, it may be possible to further streamline this approach to achieve the best possible results for engraftment, while decreasing the risk for GVHD and transplant-related toxicity.
